Cover Image
Market Research Report

Retinal Vein Occlusion (RVO) - Epidemiology Forecast - 2030

Published by DelveInsight Business Research LLP Product code 963741
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Retinal Vein Occlusion (RVO) - Epidemiology Forecast - 2030
Published: October 14, 2020 Content info: 100 Pages
Description

DelveInsight's 'Retinal Vein Occlusion (RVO)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted RVO epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Retinal Vein Occlusion (RVO) Understanding

Retinal vein occlusion, one of the most frequently occurring retinal vascular disorders in elderly patients, develops predominantly in individuals over age 65 years. The main risk factors for RVO include age and systemic vascular disorders.It is categorized into central RVO (CRVO) and branch RVO (BRVO) according to the site of blockage in the retinal vein. CRVO is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRVO consists of major branch RVO (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch RVO (when only one of the macular venules is occluded). Macular edema is the major complication of significant visual loss in patients with CRVO and BRVO, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.

The initial examination of a patient with an RVO includes all relevant aspects of the comprehensive adult medical eye evaluation, with particular attention to those aspects related to retinal vascular disease. Several tests are being used for the diagnosis of RVO such as Optical coherence tomography (OCT), and fluorescein angiography (FA). Apart from this, Systemic evaluation is often performed in patients with CRVO and is directed by the patient's age, coexisting risk factors, and medical history. In RVO, intravitreal steroids and anti-VEGF therapy are used in cases of macular perfusion and macular ischemia, with the laser of use in situations of neovascularization. Response to treatment may be measured by improvement of visual acuity (as a measure of photoreceptor status) and retinal thickness (as a measure of leakage).

Retinal Vein Occlusion Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of RVO, Diagnosed Prevalent Cases of RVO, Gender-specific Diagnosed Prevalent Cases of RVO, Age-specific Diagnosed Prevalent Cases of RVO, Type-specific Diagnosed Prevalent Cases of RVO, and Treated Cases of RVO in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

RVO Detailed Epidemiology Segmentation

  • In the year 2017, the total prevalent cases of RVO were 2,225,011 cases in the 7MM, which is expected to increase in the forecast period.
  • The United States, in 2017, accounted for 1,124,718 cases prevalent cases of RVO (the highest number), which will probably rise in the year 2030. In EU-5 countries the highest number of prevalent Cases of RVO was in Germany, i.e., 206,690, in the year 2017. The lowest number of cases observed in Spain during the study period.
  • In 2017, the total diagnosed prevalent cases of RVO in the 7MM were 1,947,496.
  • In the 7MM, the total gender-specific prevalent cases of RVO were 916,868 for males and 1,030,628 for females in the year 2017
  • RVO is more frequent in the older age population. Hence, in the 7MM, the total diagnosed cases of RVO by age distribution were 1,124,790, 516,151, and 306,555 cases for the age group less than 65 years, 65-74 years, and ≥75 years, in 2017.
  • In the 7MM, CRVO contributed to 392,221 cases in 2017, and there were around 1,555,274 BRVO cases, the same year.

Scope of the Report:

  • The report covers the descriptive overview of RVO, explaining its causes, signs, and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases, Diagnosed Prevalent Cases, Ender-Specific Diagnosed Prevalent Cases, Age-Specific Diagnosed Prevalent Cases, Type-Specific Diagnosed Prevalent Cases And Treated Cases.

Report Highlights:

  • 11-Year Forecast of RVO
  • 7MM Coverage of RVO
  • Prevalent Cases of RVO in the 7MM
  • Diagnosed Prevalent Cases of RVO in the 7MM
  • Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM
  • Age-specific Diagnosed Prevalent Cases of RVO in the 7MM
  • Type-specific Diagnosed Prevalent Cases of RVO in the 7MM
  • Treated Cases of RVO in the 7MM

Key Questions Answered

  • What are the disease risk, burden, and unmet needs of RVO?
  • What is the historical RVO patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of RVO at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to RVO?
  • Out of the countries mentioned above, which country would have the highest incident population of RVO during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The RVO report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM RVO market.
  • Quantify patient populations in the 7MM RVO market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the specific type of RVO that presents the best opportunities for RVO therapeutics in each of the markets covered.
  • The RVO epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The RVO epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents
Product Code: DIEI0200

Table of Contents

1. Key Insights

2. Executive Summary of Retinal Vein Occlusion (RVO)

3. RVO: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Risk Factors and Causes
  • 3.4. Pathophysiology
  • 3.5. Diagnosis
    • 3.5.1. Optical coherence tomography
    • 3.5.2. Fluorescein angiography
    • 3.5.3. Systemic Evaluation
    • 3.5.4. Optical coherence tomography angiography (OCTA)
    • 3.5.5. Fundus Autofluorescence
    • 3.5.6. Laboratory Test
    • 3.5.7. European Society of Retina Specialists Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Epidemiology Key Findings
  • 4.2. Assumptions and Rationale
  • 4.3. Epidemiology Scenario: 7MM
    • 4.3.1. Total Prevalent Cases of RVO in the 7MM
    • 4.3.2. Total Diagnosed Prevalent cases of RVO in the 7MM
    • 4.3.3. Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM
    • 4.3.4. Age-specific Diagnosed Prevalent Cases of RVO in the 7MM
    • 4.3.5. Type-specific Diagnosed Prevalent Cases of RVO in the 7MM
    • 4.3.6. Treated cases of RVO in the 7MM
  • 4.4. The United States Epidemiology
    • 4.4.1. Total Prevalent Cases of RVO in the United States
    • 4.4.2. Total Diagnosed Prevalent cases of RVO in the United States
    • 4.4.3. Gender-specific Diagnosed Prevalent Cases of RVO in the United States
    • 4.4.4. Age-specific Diagnosed Prevalent Cases of RVO in the United States
    • 4.4.5. Type-specific Diagnosed Prevalent Cases of RVO in the United States
    • 4.4.6. Treated cases of RVO in the United States
  • 4.5. EU-5 Epidemiology
  • 4.6. Germany
    • 4.6.1. Total Prevalent Cases of RVO in Germany
    • 4.6.2. Total Diagnosed Prevalent cases of RVO in Germany
    • 4.6.3. Gender-specific Diagnosed Prevalent Cases of RVO in Germany
    • 4.6.4. Age-specific Diagnosed Prevalent Cases of RVO in Germany
    • 4.6.5. Type-specific Diagnosed Prevalent Cases of RVO in Germany
    • 4.6.6. Treated cases of RVO in Germany
  • 4.7. France
    • 4.7.1. Total Prevalent Cases of RVO in France
    • 4.7.2. Total Diagnosed Prevalent cases of RVO in France
    • 4.7.3. Gender-specific Diagnosed Prevalent Cases of RVO in France
    • 4.7.4. Age-specific Diagnosed Prevalent Cases of RVO in France
    • 4.7.5. Type-specific Diagnosed Prevalent Cases of RVO in France
    • 4.7.6. Treated cases of RVO in France
  • 4.8. Italy
    • 4.8.1. Total Prevalent Cases of RVO in Italy
    • 4.8.2. Total Diagnosed Prevalent cases of RVO in Italy
    • 4.8.3. Gender-specific Diagnosed Prevalent Cases of RVO in Italy
    • 4.8.4. Age-specific Diagnosed Prevalent Cases of RVO in Italy
    • 4.8.5. Type-specific Diagnosed Prevalent Cases of RVO in Italy
    • 4.8.6. Treated cases of RVO in Italy
  • 4.9. Spain
    • 4.9.1. Total Prevalent Cases of RVO in Spain
    • 4.9.2. Total Diagnosed Prevalent cases of RVO in Spain
    • 4.9.3. Gender-specific Diagnosed Prevalent Cases of RVO in Spain
    • 4.9.4. Age-specific Diagnosed Prevalent Cases of RVO in Spain
    • 4.9.5. Type-specific Diagnosed Prevalent Cases of RVO in Spain
    • 4.9.6. Treated cases of RVO in Spain
  • 4.10. The United Kingdom
    • 4.10.1. Total Prevalent Cases of RVO in the United Kingdom
    • 4.10.2. Total Diagnosed Prevalent cases of RVO in the United Kingdom
    • 4.10.3. Gender-specific Diagnosed Prevalent Cases of RVO in the United Kingdom
    • 4.10.4. Age-specific Diagnosed Prevalent Cases of RVO in the United Kingdom
    • 4.10.5. Type-specific Diagnosed Prevalent Cases of RVO in the United Kingdom
    • 4.10.6. Treated cases of RVO in the United Kingdom
  • 4.11. Japan Epidemiology
    • 4.11.1. Total Prevalent Cases of RVO in Japan
    • 4.11.2. Total Diagnosed Prevalent cases of RVO in Japan
    • 4.11.3. Gender-specific Diagnosed Prevalent Cases of RVO in Japan
    • 4.11.4. Age-specific Diagnosed Prevalent Cases of RVO in Japan
    • 4.11.5. Type-specific Diagnosed Prevalent Cases of RVO in Japan
    • 4.11.6. Treated cases of RVO in Japan

5. Recognized Establishments

6. Appendix

  • 6.1. Bibliography
  • 6.2. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables

  • Table 1: Summary of Retinal Vein Occlusion (RVO), Epidemiology, and Key Events (2017-2030)
  • Table 2: Total Prevalent Cases of RVO in the 7MM (2017-2030)
  • Table 3: Total Diagnosed Prevalent cases of RVO in the 7MM (2017-2030)
  • Table 4: Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM (2017-2030)
  • Table 5: Age-specific Prevalent Cases of RVO in the 7MM (2017-2030)
  • Table 6: Type-specific Diagnosed Prevalent Cases of RVO in the 7MM (2017-2030)
  • Table 7: Total Treated cases of RVO in the 7MM (2017-2030)
  • Table 8: Total Prevalent Cases of RVO in the United States (2017-2030)
  • Table 9: Total Diagnosed Prevalent cases of RVO in the United States (2017-2030)
  • Table 10: Gender-specific Diagnosed Prevalent Cases of RVO in the United States (2017-2030)
  • Table 11: Age-specific Prevalent Cases of RVO in the United States (2017-2030)
  • Table 12: Type-specific Diagnosed Prevalent Cases of RVO in the United States (2017-2030)
  • Table 13:Total Treated cases of RVO in the US (2017-2030)
  • Table 14: Total Prevalent Cases of RVO in Germany (2017-2030)
  • Table 15: Total Diagnosed Prevalent cases of RVO in Germany (2017-2030)
  • Table 16: Gender-specific Diagnosed Prevalent Cases of RVO in Germany (2017-2030)
  • Table 17: Age-specific Prevalent Cases of RVO in Germany (2017-2030)
  • Table 18: Type-specific Diagnosed Prevalent Cases of RVO in Germany (2017-2030)
  • Table 19: Total Treated cases of RVO in Germany (2017-2030)
  • Table 20:Total Prevalent Cases of RVO in France (2017-2030)
  • Table 21: Total Diagnosed Prevalent cases of RVO in France (2017-2030)
  • Table 22: Gender-specific Diagnosed Prevalent Cases of RVO in France (2017-2030)
  • Table 23: Age-specific Prevalent Cases of RVO in France (2017-2030)
  • Table 24: Type-specific Diagnosed Prevalent Cases of RVO in France (2017-2030)
  • Table 25: Total Treated cases of RVO in France (2017-2030)
  • Table 26: Total Prevalent Cases of RVO in Italy (2017-2030)
  • Table 27: Total Diagnosed Prevalent cases of RVO in Italy (2017-2030)
  • Table 28: Gender-specific Diagnosed Prevalent Cases of RVO in Italy (2017-2030)
  • Table 29: Age-specific Prevalent Cases of RVO in Italy (2017-2030)
  • Table 30: Type-specific Diagnosed Prevalent Cases of RVO in Italy (2017-2030)
  • Table 31: Total Treated cases of RVO in Italy (2017-2030)
  • Table 32:Total Prevalent Cases of RVO in Spain (2017-2030)
  • Table 33: Total Diagnosed Prevalent cases of RVO in Spain (2017-2030)
  • Table 34: Gender-specific Diagnosed Prevalent Cases of RVO in Spain (2017-2030)
  • Table 35: Age-specific Prevalent Cases of RVO in Spain (2017-2030)
  • Table 36: Type-specific Diagnosed Prevalent Cases of RVO in Spain (2017-2030)
  • Table 37: Total Treated cases of RVO in Spain (2017-2030)
  • Table 38:Total Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Table 39: Total Diagnosed Prevalent cases of RVO in the United Kingdom (2017-2030)
  • Table 40: Gender-specific Diagnosed Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Table 41: Age-specific Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Table 42: Type-specific Diagnosed Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Table 43: Total Treated cases of RVO in the United Kingdom (2017-2030)
  • Table 44: Total Prevalent Cases of RVO in Japan (2017-2030)
  • Table 45: Total Diagnosed Prevalent cases of RVO in Japan (2017-2030)
  • Table 46: Gender-specific Diagnosed Prevalent Cases of RVO in Japan (2017-2030)
  • Table 47: Age-specific Prevalent Cases of RVO in Japan (2017-2030)
  • Table 48: Type-specific Diagnosed Prevalent Cases of RVO in Japan (2017-2030)
  • Table 49: Total Treated cases of RVO in Japan (2017-2030)

List of Figures

  • Figure 1: RVO SWOT Analysis
  • Figure 2: Changes in the eye
  • Figure 3: CRVO with hemorrhage
  • Figure 4: Branch Retinal Vein Occlusion
  • Figure 5: Signs and symptoms
  • Figure 6: Risk factors of RVO
  • Figure 7: Pathophysiology of RVO
  • Figure 8: Optical coherence tomography
  • Figure 9: Fluorescein angiography
  • Figure 10: Fundus autofluorescence
  • Figure 11: Total Prevalent Cases of RVO in the 7MM (2017-2030)
  • Figure 12: Total Diagnosed Prevalent cases of RVO in the 7MM (2017-2030)
  • Figure 13: Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM (2017-2030)
  • Figure 14: Age-specific Diagnosed Prevalent Cases of RVO in the 7MM (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of RVO in the 7MM (2017-2030)
  • Figure 16: Treated cases of RVO in the 7MM (2017-2030)
  • Figure 17: Total Prevalent Cases of RVO in the United States (2017-2030)
  • Figure 18: Total Diagnosed Prevalent cases of RVO in the United States (2017-2030)
  • Figure 19: Gender-specific Diagnosed Prevalent Cases of RVO in the United States (2017-2030)
  • Figure 20:Age-specific Diagnosed Prevalent Cases of RVO in the United States (2017-2030)
  • Figure 21: Type-specific Diagnosed Prevalent Cases of RVO in the United States (2017-2030)
  • Figure 22: Treated cases of RVO in the United States (2017-2030)
  • Figure 23: Total Prevalent Cases of RVO in Germany (2017-2030)
  • Figure 24: Total Diagnosed Prevalent cases of RVO in Germany (2017-2030)
  • Figure 25: Gender-specific Diagnosed Prevalent Cases of RVO in Germany (2017-2030)
  • Figure 26: Age-specific Diagnosed Prevalent Cases of RVO in Germany (2017-2030)
  • Figure 27: Type-specific Diagnosed Prevalent Cases of RVO in Germany (2017-2030)
  • Figure 28: Treated cases of RVO in Germany (2017-2030)
  • Figure 29: Total Prevalent Cases of RVO in France (2017-2030)
  • Figure 30: Total Diagnosed Prevalent cases of RVO in France (2017-2030)
  • Figure 31: Gender-specific Diagnosed Prevalent Cases of RVO in France (2017-2030)
  • Figure 32: Age-specific Diagnosed Prevalent Cases of RVO in France (2017-2030)
  • Figure 33: Type-specific Diagnosed Prevalent Cases of RVO in France (2017-2030)
  • Figure 34: Treated cases of RVO in France (2017-2030)
  • Figure 35: Total Prevalent Cases of RVO in Italy (2017-2030)
  • Figure 36: Total Diagnosed Prevalent cases of RVO in Italy (2017-2030)
  • Figure 37: Gender-specific Diagnosed Prevalent Cases of RVO in Italy (2017-2030)
  • Figure 38: Age-specific Diagnosed Prevalent Cases of RVO in Italy (2017-2030)
  • Figure 39: Type-specific Diagnosed Prevalent Cases of RVO in Italy (2017-2030)
  • Figure 40: Treated cases of RVO in Italy (2017-2030)
  • Figure 41: Total Prevalent Cases of RVO in Spain (2017-2030)
  • Figure 42: Total Diagnosed Prevalent cases of RVO in Spain (2017-2030)
  • Figure 43: Gender-specific Diagnosed Prevalent Cases of RVO in Spain (2017-2030)
  • Figure 44: Age-specific Diagnosed Prevalent Cases of RVO in Spain (2017-2030)
  • Figure 45: Type-specific Diagnosed Prevalent Cases of RVO in Spain (2017-2030)
  • Figure 46: Treated cases of RVO in Spain (2017-2030)
  • Figure 47: Total Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Figure 48: Total Diagnosed Prevalent cases of RVO in the United Kingdom (2017-2030)
  • Figure 49: Gender-specific Diagnosed Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Figure 50: Age-specific Diagnosed Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Figure 51: Type-specific Diagnosed Prevalent Cases of RVO in the United Kingdom (2017-2030)
  • Figure 52: Treated cases of RVO in the United Kingdom (2017-2030)
  • Figure 53: Total Prevalent Cases of RVO in Japan (2017-2030)
  • Figure 54: Total Diagnosed Prevalent cases of RVO in Japan (2017-2030)
  • Figure 55: Gender-specific Diagnosed Prevalent Cases of RVO in Japan (2017-2030)
  • Figure 56: Age-specific Diagnosed Prevalent Cases of RVO in Japan (2017-2030)
  • Figure 57: Type-specific Diagnosed Prevalent Cases of RVO in Japan (2017-2030)
  • Figure 58: Treated cases of RVO in Japan (2017-2030)
Back to Top